Last reviewed · How we verify
Fluorodopa F18 (FLUORODOPA)
At a glance
| Generic name | FLUORODOPA |
|---|---|
| Sponsor | Feinstein |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2019 |
Approved indications
- Evaluation of suspected Parkinsonian syndromes
Common side effects
- Pain
- Fatigue
- Nausea
- Diarrhea
Drug interactions
- AADC inhibitors (e.g., carbidopa, benserazide)
- Dopamine agonists, dopamine reuptake inhibitors, dopamine releasing agents (DRAs), peripheral COMT inhibitors, MAO inhibitors
Key clinical trials
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Diagnosis of Pheochromocytoma (PHASE1)
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Natural History of Familial Carcinoid Tumor
- [18F]F-DOPA Imaging in Patients With Autonomic Failure (PHASE1)
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors (PHASE2)
- Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time
- 18F-DOPA II - PET Imaging Optimization (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluorodopa F18 CI brief — competitive landscape report
- Fluorodopa F18 updates RSS · CI watch RSS
- Feinstein portfolio CI